No abstract

ContextAlthough the overt hyperthyroidism treatment during pregnancy is mandatory, unfortunately, few studies have evaluated the impact of treatment on reducing maternal and fetal outcomes.ObjectiveThis study aimed to demonstrate whether treatment to control hyperthyroidism manifested during pregnancy can potentially reduce maternal-fetal effects compared with euthyroid pregnancies through a systematic review with meta-analysis.Data SourceMEDLINE (PubMed), Embase, Cochrane Library Central, LILACS/BIREME until May 2021.Study SelectionStudies that compared, during the gestational period, treated women with hyperthyroidism versus euthyroid women. The following outcomes of this comparison were: pre-eclampsia, abruptio placentae, fetal growth retardation, gestational diabetes, postpartum hemorrhage, low birth weight, stillbirth, spontaneous abortions, premature birth.Data ExtractionTwo independent reviewers extracted data and performed quality assessments. Dichotomous data were analyzed by calculating risk differences (DR) with fixed and random effect models according to the level of heterogeneity.Data SynthesisSeven cohort studies were included. The results of the meta-analysis indicated that there was a lower incidence of preeclampsia (p=0.01), low birth weight (p=0.03), spontaneous abortion (p<0.00001) and preterm birth (p=0.001) favouring the euthyroid pregnant group when compared to those who treated hyperthyroidism during pregnancy. However, no statistically significant differences were observed in the outcomes: abruptio placentae, fetal growth retardation, gestational diabetes mellitus, postpartum hemorrhage, and stillbirth.ConclusionsOur findings demonstrated that treating overt hyperthyroidism in pregnancy is mandatory and appears to reduce some potential maternal-fetal complications, despite there still being a residual risk of negative outcomes.

No abstract

No abstract

satisfaction scores and post-op complications compared to manual THA (mTHA). The purpose of this study was to compare robotic-assisted vs. manual total hip arthroplasty index and post-discharge utilization and costs in a 90-day episode-of-care (EOC). Methods: THA procedures were identified using the Medicare 100% Standard Analytic Files. Members included patients with RATHA or mTHA between 10/1/2015-10/1/2018. Propensity score matching (PSM) was performed in a 1-to-5 ratio, robotic to manual. After PSM, 938 rTHA and 4,670 mTHA were identified and included for analysis. Ninety-day episode-of-care cost, index cost, LOS, post-index rehab utilization and costs were assessed. Results: RATHA patients were less likely to have postindex IPR or SNF admissions (0.64% vs. 2.68%; p,0.0001 and 20.79% vs. 24.99%; p=0.0041, respectively). RATHA patients used fewer days in post-index inpatient and SNF care (7.15 vs. 7.91; p=0.8029 and 17.98 vs. 19.64; p=0.5080, respectively) and used fewer HHA visits, (14.06 vs. 15.00; p=0.